MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, NXTC had $2,432K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$2,432K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-8,624 -37,784
Depreciation and amortization
533 1,287
Amortization of premiums and discounts on marketable securities
46 386
Stock-based compensation
600 1,951
Noncash operating lease expense
148 288
Prepaid expenses and other assets
-1,195 1,716
Accounts payable
-153 -2,809
Accrued liabilities and other liabilities
-367 -4,016
Lease liabilities
-254 -488
Other long-term liabilities
-34 -66
Net cash used in operating activities
-6,268 -35,707
Sales and maturities of marketable securities
8,700 37,558
Purchases of marketable securities
0 26,705
Net cash provided by investing activities
8,700 10,853
Proceeds from issuance of common stock
0 2,000
Proceeds from shares issued under espp
0 19
Net cash provided by financing activities
0 2,019
Net increase (decrease) in cash and cash equivalents
2,432 -22,835
Cash and cash equivalents at beginning of period
27,727 -
Cash and cash equivalents at end of period
7,324 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

NextCure, Inc. (NXTC)

NextCure, Inc. (NXTC)